BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare CV&Met Disease Analysis: Type 2 Diabetes

September 14, 2022

The type 2 diabetes market is dynamic and complex. In the non-insulin segment, while older generic drugs are widely used, especially first-line metformin in the US and EU, the more novel branded drugs are used in a sizable minority of patients, generating over $30bn in sales in 2021. The DPP-IV inhibitors have historically been the most commonly used of these, due to their safety and tolerability, albeit with intermediate efficacy, but GLP-1 receptor agonists and SGLT-2 inhibitors have now overtaken them in usage in the important US market and have curtailed their growth ex-US. The increased usage of GLP-1 receptor agonists and SGLT-2 inhibitors has been spurred by recommendations starting in a 2018 ADA/EASD consensus report for patients with relevant co-morbidities due to benefits on major adverse cardiovascular events (MACE) and, for the SGLT-2 inhibitors in particular, heart failure and renal impairment, along with related label expansions. This is expected to continue to grow these classes, though intense pricing competition, with increasing rebates in the US, is typical across the indication. However, loss of exclusivity will start to take a toll on all of these classes over the next 10 years, particularly starting with patent expirations for the leading DPP-IV inhibitor Januvia in 2022–23. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Diabetes Mellitus, Type II
Back to the top Back to the top